Clinical Trials Logo

Clinical Trial Summary

Self-injurious behavior is behavior in which a person hurts or harms himself. This behavior sometimes occurs in people with mental retardation or autism. This study will evaluate self-injurious behavior in people with mental retardation or autism and will test the effectiveness of new treatments.


Clinical Trial Description

It is unknown why some people with mental retardation and/or autism repeatedly and persistently injure themselves, some to the point of tissue damage and permanent scarring. Unraveling this mystery poses paradoxical biomedical and behavioral science questions and creates deeply troubling problems for practitioners and family members of affected individuals. Over the past decade, many cases of self-injurious behavior (SIB) have been treated successfully using behavioral interventions that teach communication and other functional skills. However, practical problems of implementation, costs associated with long-term treatment, and cases with no clear social profile suggest that there is still much to be learned about why people self-injure. Some forms of self-injury may involve intense stimulation of body sites sufficient to elicit the release and receptor binding of endogenous opioid peptides. This study will evaluate variables common to SIB and the neurophysiology of pain regulation. The study will also clarify the role of the endogenous opioids and pain mechanisms in self-injury.

Participants with mild to profound mental retardation and/or autism will be observed for frequency of self-injury, duration and intensity of self-injurious behavior, and where on the body that behavior is directed. Following this characterization, participants’ saliva will be noninvasively examined for substance P, met-enkephalin, and cortisol as markers for altered pain transmission and predictors of response to treatment. After screening and SIB subtyping (i.e., social, nonsocial, or mixed), 37 participants whose self-injury is primarily nonsocial or mixed will be evaluated over 16 weeks. Participants will be randomized to receive either transcutaneous electric nerve stimulation (TENS, an opioid agonist treatment) or naltrexone (an opioid antagonist treatment). Participants whose self-injury is primarily socially motivated will be evaluated with TENS and will receive behavioral interventions through a technical assistance service delivery model. Follow-up evaluations will occur at Months 3 and 6. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00065936
Study type Interventional
Source Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contact
Status Active, not recruiting
Phase Phase 3
Start date July 1997
Completion date June 2002

See also
  Status Clinical Trial Phase
Completed NCT02791321 - Fragility Assessment in Adults With ADHD and Mental Retardation N/A
Recruiting NCT01908400 - Safety and Efficacy of BMMNCin Patients With Mental Retardation Phase 1/Phase 2
Withdrawn NCT02245724 - Stem Cell Therapy in Mental Retardation Phase 1
Completed NCT00156221 - MR Scanning of Very Young Children With Severe Developmental Disorders N/A
Recruiting NCT00491478 - Repetitive Behavior Disorders in People With Severe Mental Retardation Phase 3
Terminated NCT02797418 - "Cognitus & Moi": a New Cognitive Remediation Tool N/A
Completed NCT00758108 - Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Completed NCT01430845 - Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay
Not yet recruiting NCT02214745 - Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community N/A
Active, not recruiting NCT00552526 - Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Phase 4
Completed NCT02943304 - Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
Completed NCT00491894 - Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Phase 3
Completed NCT01291238 - School Intervention With Daily Physical Activity and Healthy Food for Students With an Intellectual Disability. N/A
Completed NCT01456910 - Resistance Training Program, Labor Inclusion, Intellectual Disability N/A
Completed NCT00065273 - Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay Phase 3
Completed NCT00506259 - Treatment Strategies for Children With Smith-Magenis Syndrome Phase 1
Not yet recruiting NCT05442229 - A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years
Active, not recruiting NCT06370793 - Ningbo Severe Mental Disorders Cohort
Completed NCT01517048 - Brain-Derived Neurotrophic Factor in Obesity and Brain Function
Completed NCT03847753 - Exploring the Comorbidity Between Mental Disorders and General Medical Conditions